Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients

Bevacizumab (Bv) remains frequently prescribed in glioblastoma (GBM) patients, especially at recurrence. We conducted a prospective clinical trial with 29 recurrent GBM patients treated with Bv alone with a longitudinal follow-up of different circulating immune cells [complete blood count, myeloid-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Quillien, Véronique, Carpentier, Antoine F., Gey, Alain, Avril, Tony, Tartour, Eric, Sejalon, Floraly, Campillo-Gimenez, Boris, Vauleon, Elodie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529384/
https://www.ncbi.nlm.nih.gov/pubmed/30830269
http://dx.doi.org/10.1007/s00262-019-02317-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529384/
https://www.ncbi.nlm.nih.gov/pubmed/30830269
http://dx.doi.org/10.1007/s00262-019-02317-9

Ejemplares similares